Oncotype DX is used not only as a prognostic factor in ER-positive, HER2-negative BC, but according to the results of the TAILORx trial, it is also a predictor of the benefits of chemotherapy in node negative patients20–23. This evidence concerns the gene ESR1 and breast cancer.